HomeBEAM • BMV
add
Beam Therapeutics Inc
Previous close
$546.25
Year range
$356.51 - $590.00
Market cap
2.19B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 14.27M | -17.01% |
Operating expense | 26.52M | 4.35% |
Net income | -96.67M | -0.60% |
Net profit margin | -677.47 | -21.22% |
Earnings per share | -1.17 | 4.10% |
EBITDA | -101.03M | 1.99% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 925.76M | -8.83% |
Total assets | 1.17B | -9.23% |
Total liabilities | 380.05M | -25.71% |
Total equity | 791.32M | — |
Shares outstanding | 79.59M | — |
Price to book | 54.79 | — |
Return on assets | -21.89% | — |
Return on capital | -26.99% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -96.67M | -0.60% |
Cash from operations | -88.12M | 1.85% |
Cash from investing | 24.70M | 341.43% |
Cash from financing | 1.26M | -96.57% |
Net change in cash | -62.16M | 1.70% |
Free cash flow | -42.99M | -17.18% |
About
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
CEO
Founded
2017
Website
Employees
472
